Pomerantz LLP is investigating claims on behalf of investors of Astrana Health, Inc. following allegations of securities fraud. The investigation was prompted by a report from Glass House Research accusing Astrana of relying on aggressive acquisitions and subjective management estimates instead of organic growth, and raising concerns about a $545 million related-party loan and potential Medicare regulatory risks in 2027. After the report's release, Astrana's stock price fell by 9.02%. The law firm is advising affected investors to contact them for potential class action participation.
Astrana Health, Inc. faces an investor investigation following allegations of securities fraud. For readers following the health sector, here is Pluang's market snapshot as of Oct 14, 2026 03:41 WIB: out of 128 priced US health stocks, 29 rose and 99 fell. Notable movers include TXG at USD 71.79 with a 4.52% decline and 100% buy order activity, ERAS at USD 14.78 down 4.40% with 100% sell order activity, and NBIX at USD 135.50 down 4.15% with a nearly balanced buy/sell order split.
Applied Materials projects sustained demand for its chipmaking equipment driven by AI infrastructure growth, expecting faster spending on wafer fab equipment through 2030. The company aims to increase its market share by over 2 percentage points from...
Gordon Haskett Capital Corporation set a $105 price target for Ollie's Bargain Outlet, suggesting an 18.1% upside from its current price around $89. The company’s board approved an additional $500 million share repurchase authorization, increasing to...
FRUIT Holdings, Inc. introduced PAVE, a new protocol designed to allow AI systems to call on human judgment and authority when needed. This approach ensures that human input retains its value, authority, and attribution within AI workflows, addressin...
AngioDynamics reported a 6.9% revenue increase to $80.9 million and a narrowed adjusted loss of 4 cents per share for Q1 fiscal 2027, with strong Med Tech sales growing 13.2%. Despite beating earnings expectations and improved gross margin, the stock...
Pomerantz LLP is investigating Cellebrite DI Ltd. for potential securities fraud following the company's Q2 2026 financial report, which showed Annual Recurring Revenue (ARR) below guidance and a lowered full-year ARR forecast. The company also abrup...
